Recombinant Human HRAS/GTPase Hras protein (His tag)

SKU: PDEH101024

Size:100μg

Storage:Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.

Shipping:This product is provided as lyophilized powder which is shipped with ice packs.

Exp date:12 months

Category ID_II:Recombinant Proteins

Category ID_III:Others

Abbreviation:HRAS;GTPase Hras

Target Synonym:C-BAS/HAS;C-H-RAS;C-HA-RAS1;CTLO;H-RASIDX;HAMSV;HRAS1;RASH1;p21ras

Research Areas:Signal Transduction;Tags & Cell Markers;Cell biology;Cancer;epigenetics and nuclear signal;

Conjugation:

Target Species:Human

Expression Host:E.coli

Application:

Fusion tag:N-His

UNIProt ID:P01112

Accession:P01112

Background:HRas, also known as HRAS, belongs to the small GTPase superfamily, Ras family and is widely expressed. It functions in signal transduction pathways. HRas can bind GTP and GDP, and they have intrinsic GTPase activity. It undergoes a continuous cycle of de-and re-palmitoylation, which regulates its rapid exchange between the plasma membrane and the Golgi apparatus. Defects in HRAS are the cause of faciocutaneoskeletal syndrome (FCSS). FCSS is arare condition characterized by prenatally increased growth, postnatal growth deficiency, mental retardation, distinctive facial appearance, cardiovascular abnormalities, tumor predisposition, skin and musculoskeletal abnormalities. Defects in HRAS also can cause congenital myopathy with excess of muscle spindles. HRAS deficiency may be a cause of susceptibility to Hurthle cell thyroid carcinoma. It has been shown that defects in HRAS can cause susceptibility to bladder cancer which is a malignancy

Concentration:

Activity:Not validated for activity

Sequence:Met 1-Cys 186

Purity: > 95% as determined by reducing SDS-PAGE.

Formulation:Lyophilized from sterile PBS, pH 7.4.
Normally 5%-8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the printed manual.

Reconstitution:It is recommended that sterile water be added to the vial to prepare a stock solution of 0.5 mg/mL. Concentration is measured by UV-Vis.

Endotoxin:< 10 EU/mg of the protein as determined by the LAL method.

Calculated MW:20.4 kDa

ObservedMW:25 kDa